Clinical trials: Multiple Sclerosis (Relapsing Remitting)
Multiple Sclerosis
Relationship Between Single- and Dual-Task Obstacle Crossing Performance and Fatigue and Disability in Multiple Sclerosis
This cross-sectional observational study aims to investigate the relationship between obstacle crossing performance under single-task and dual-task conditions and the levels of fatigue and disability in individuals with…
- Trial name
- NCT07736482
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Afyonkarahisar Health Sciences University
Multiple Sclerosis, Relapsing-Remitting
Cellular microRNA Signatures in Multiple Sclerosis
A limited number of studies on microRNA expression variation in immune cells have been reported in relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- SEP-MIR (NCT05290688)
- Testing
- 50 ml blodd sampling
- Where
- France
- Volunteers
- 20 people
- Sponsor
- Institut Pasteur
Multiple Sclerosis, Relapsing-Remitting
Minocycline as add-on to Interferon Beta-1a [IFN Beta-1a] (Rebif®) in Relapsing-Remitting Multiple Sclerosis [RRMS]
This is a multicentric, double-blind, placebo-controlled, randomized, parallel group study to estimate the effect of minocycline as add-on to interferon beta-1a (IFN beta-1a) in subjects with relapsing-remitting multiple…
- Trial name
- RECYCLINE (NCT01134627)
- Testing
- Minocycline
- Where
- Denmark
- Volunteers
- 305 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Multiple Sclerosis, Relapsing-Remitting
Effects of a Combined Supplementation of Conjugated Linoleic Acid (CLA) and Probiotics (Vivomixx®) as add-on to a First-line Immunotherapy in Relapsing-remitting Multiple Sclerosis
The goal of this randomized, double-blind, placebo-controlled multicenter study is to investigate whether the combination of food supplementation with Tonalin® and specific probiotics is a safe and effective add-on to first-line…
- Trial name
- CLAProMS (NCT05920018)
- Testing
- Vivomixx®, Conjugated linoleic acid (CLA/Tonalin® FFA 80)
- Where
- 4 sites in Germany
- Volunteers
- 100 people
- Sponsor
- Universität Münster
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis
Oral Guanabenz for Multiple Sclerosis
Background: People with multiple sclerosis (MS) get lesions in their brain and spinal cord. These cause neurological symptoms and sometimes disability.
- Trial name
- NCT02423083
- Testing
- Guanabenz
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Multiple Sclerosis
VALIDATE: Factor VIII Trending for MS Relapse
Multiple sclerosis (MS) patients hospitalized with an acute motor or visual relapse will be consented. Factor VIII-related labs will be systematically drawn for six months.
- Trial name
- NCT04082468
- Testing
- Blood sample collection for coagulation profile
- Where
- United States
- Sponsor
- St. Joseph's Hospital and Medical Center, Phoenix
Relapsing Remitting Multiple Sclerosis (RRMS), Secondary Progressive Multiple Sclerosis (SPMS)
Portuguese Observational Survey to Assess Drug Adherence in Patients With Multiple Sclerosis After Conversion to Betaferon by Using Elements of the BetaPlus Program - Nurse Support, Auto-injectors
This is an observational survey to assess the factors that influence adherence to Betaferon therapy in multiple sclerosis patients using elements of the BetaPlus support program, including the nurse support and auto-injectors.
- Trial name
- POR-BetaPlus (NCT01235455)
- Testing
- Interferon beta-1b (Betaseron, BAY86-5046)
- Where
- Portugal
- Volunteers
- 10 people
- Sponsor
- Bayer
Relapsing-Remitting Multiple Sclerosis
A Pilot Trial to Test the Feasibility of Prolonged Fasting and Ketogenic Diet in Relapsing-remitting Multiple Sclerosis
It is well accepted that nutrition as an environmental factor is involved in the pathogenesis of multiple sclerosis. But is there a role for prolonged fasting and ketogenic low glycemic load treatment to alter the course of…
- Trial name
- IGEL (NCT01538355)
- Testing
- Prolonged Fasting, Ketogenic low glycemic load treatment, Control diet
- Where
- Germany
- Volunteers
- 48 people
- Sponsor
- Charite University, Berlin, Germany
Relapsing-remitting Multiple Sclerosis
The HIt HArd and hiT Early in Multiple Sclerosis Trial
The HiHat trial is a Phase 2 study aimed at evaluating the safety and feasibility of sequential treatment with rituximab and cladribine in patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- HiHat (NCT07517185)
- Testing
- Sequential treatment with rituximab and cladribine
- Where
- 4 sites in Sweden
- Volunteers
- 60 people
- Sponsor
- Uppsala University
Multiple Sclerosis
Exploratory Study to Assess Clinical Response to Gilenya® (Fingolimod) in Hispanics With RRMS
Gilenya (fingolimod) is approved for multiple sclerosis. However, it is unclear of its clinical effect in the Hispanics with MS given that clinical studies had limited representation of this population.
- Trial name
- NCT01592097
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- University of Southern California
Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting
Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS
Rationale: Ocrelizumab is widely and effectively used to treat relapsing multiple sclerosis (RMS). Phase II studies and data from large patient cohorts indicate that rituximab, another anti-CD20 monoclonal antibody, is probably…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis, Relapsing-Remitting, Demyelinating Autoimmune Diseases, CNS, Autoimmune Diseases of the Nervous System
- Trial name
- Noisy Rebels (NCT05834855)
- Testing
- Rituximab
- Where
- Netherlands
- Volunteers
- 200 people
- Sponsor
- Amsterdam UMC, location VUmc
Relapsing Remitting Multiple Sclerosis
Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants
The purpose of this study is to evaluate the impact of an early treatment with Natalizumab on the management of the progressive nature of Relapsing Remitting Multiple Sclerosis (RRMS).
- Trial name
- TYPIFI (NCT04832399)
- Testing
- Natalizumab
- Where
- 18 sites in Portugal
- Volunteers
- 60 people
- Sponsor
- Biogen
Multiple Sclerosis (MS) - Relapsing-remitting
Combined Motor Imagery and Vestibular Rehab for MS
This trial investigates the first combined use of motor imagery and vestibular rehabilitation in multiple sclerosis, aiming to evaluate their joint effect on balance, cognition, and quality of life.
- Trial name
- MIVR-MS (NCT07230015)
- Testing
- Motor Imagery + Vestibular Rehabilitation group, Conventional therapy group
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Medipol University
Multiple Sclerosis, Relapsing-Remitting
A Study to Evaluate Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Natalizumab (BG00002) Administered Subcutaneously to Japanese Participants With Relapsing-Remitting Multiple Sclerosis
The primary objective of this study is to evaluate the efficacy of natalizumab 300 milligrams (mg) subcutaneous (SC) every 4 weeks (Q4W) administrations up to 24 weeks in Japanese participants with relapsing-remitting multiple…
- Trial name
- NCT05265728
- Testing
- Natalizumab
- Where
- 12 sites in Japan
- Volunteers
- 21 people
- Sponsor
- Biogen
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
Home Based Functional Balance Intervention for Multiple Sclerosis
The study involves a two-arm, Phase 1, randomized controlled clinical trial designed to establish the feasibility and effects of a Functional Balance Intervention (FBI) on physical and cognitive function, as well as measures of…
- Conditions
- Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis (MS) Secondary Progressive
- Trial name
- HomeFBIinMS (NCT07355387)
- Testing
- Multicomponent balance intervention consisting of four components including dual-tasking, functional strength, vestibular and dynamic balance., Stretching
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- University of Illinois at Chicago
Multiple Sclerosis, Multiple Sclerosis (MS) - Relapsing-remitting
MS Synchronous vs Asynchronous Exercise Study
This randomized controlled study aims to compare the effects of synchronous and asynchronous exercise programs on individuals diagnosed with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT07233902
- Testing
- Combined Exercise Program (Synchronous Delivery), Combined Exercise Program (Asynchronous Delivery)
- Where
- Turkey (Türkiye)
- Volunteers
- 16 people
- Sponsor
- Yeditepe University
Multiple Sclerosis, Relapsing-Remitting
Investigating the Effect of Ocrelizumab in African Americans and Caucasians With Relapsing Multiple Sclerosis
The investigators intend to examine the effects of ocrelizumab use in African American multiple sclerosis disease course compared to Caucasian disease course utilizing imaging measures with magnetic resonance imaging (MRI) and…
- Trial name
- NCT04458688
- Testing
- Observation of Ocrelizumab as Treatment in RRMS Patients
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- Wayne State University
Multiple Sclerosis
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
This is a multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by active treatment, to evaluate the efficacy, safety and tolerability of two doses of oral administration of…
- Trial name
- CONCERTO (NCT01707992)
- Testing
- Laquinimod
- Where
- 284 sites in United States, Austria and 28 more
- Volunteers
- 2,199 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis
Identification of Retinal Perivascular Inflammation in Patients With Multiple Sclerosis Using Adaptive Optics (RETIMUS)
Using a technique called adaptive optics imaging applied on retina, investigators aim to gain access to vascular changes that could occur early in the course of Multiple Sclerosis (MS) and which could reflect vascular changes…
- Conditions
- Relapsing Remitting Multiple Sclerosis, Progressive Multiple Sclerosis, Optic Neuritis, Eye Diseases
- Trial name
- RETIMUS (NCT04289909)
- Testing
- Adaptive Optics Ophthalmoscopy (AOO)
- Where
- France
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Multiple Sclerosis
A Study to Evaluate the Safety, Tolerability and Efficacy of AIN457 in Patients With Relapsing-remitting Multiple Sclerosis
The study will assess the long-term safety and tolerability of AIN457 in patients with relapsing-remitting multiple sclerosis (RRMS).
- Trial name
- NCT01433250
- Testing
- AIN457
- Where
- 14 sites in Czechia, Russia and 1 more
- Volunteers
- 39 people
- Sponsor
- Novartis Pharmaceuticals